Results With BEXXAR

The BEXXAR therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) may be useful for patients whose disease has not responded to prior therapy or has returned after therapy and who have CD20-positive, low-grade, follicular non-Hodgkin's lymphoma or follicular non-Hodgkin's lymphoma that has transformed to a faster-growing form. BEXXAR is approved by the FDA for patients who have already received chemotherapy or a drug called Rituxan, or a combination of both. Your doctor can tell you if BEXXAR is right for you. It is not known if BEXXAR will help patients live longer. BEXXAR is not for patients who have never received treatment for their non-Hodgkin’s lymphoma. BEXXAR is given to patients only once. It is not known if BEXXAR is safe to give to patients more than once, or to give together with other types of therapy, like chemotherapy or radiation treatments.

Since everyone is different, no one can say for sure whether BEXXAR will fight your disease, or for how long. BEXXAR has been studied for over 13 years. Five studies included patients from several different treatment centers who had low-grade, follicular, or transformed lymphoma, and their lymphoma had returned after receiving several other treatments. After treatment with BEXXAR, about half of these patients showed a response. For example, their tumors had shrunk to at least half the size they were before treatment with BEXXAR, or the tumors had gone away completely and could no longer be felt by a doctor or seen on a scan.

Click here for Important Safety Information about BEXXAR

Is there anything I need to know before getting BEXXAR?¹

If you and your doctor decide that BEXXAR is right for you, there’s some Important Safety Information you should know before starting treatment. Click here for Important Safety Information about BEXXAR.

WARNINGS ¹

Treatment with BEXXAR does involve risk.

Serious Allergic Reaction: Patients may develop serious allergic reactions with the intravenous (IV) infusion of BEXXAR. In some cases, death has been reported. Medications for the treatment of severe reactions should be available for immediate use by a physician. Patients who develop severe reactions should have the infusion of BEXXAR stopped and receive appropriate medical attention.

Low Blood Counts: Most patients who received BEXXAR developed prolonged and severe low blood counts. This can lead to serious infections or bleeding problems.

Not for Pregnant Women: BEXXAR can harm a fetus when given to a pregnant woman.

Special Requirements: BEXXAR contains radioactive material and should be administered only by physicians and other healthcare workers who are qualified by training in the safe use and handling of radioactive materials.

How will I know if BEXXAR is working for me? ¹

After you receive your single course of therapy with BEXXAR, you’ll go back to your doctor for tests to check on your progress. Through physical examination, X-rays, CT scans, and possibly PET scans, your doctor will be able to determine whether your tumors have decreased since getting BEXXAR. If your tumors get smaller, it means that BEXXAR is working.

Click here for Important Safety Information about BEXXAR

Complete Prescribing Information for
BEXXAR (Tositumomab and Iodine I 131 Tositumomab)

[ RETURN TO TOP ]